Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | terminated | Phase 1 | 32 | Cartesian TherapeuticsINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Allogene TherapeuticsINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Altor BioScienceINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | Abdullah KhanOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 2 | University of ChicagoOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT00775502 | Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | terminated | Phase 1 | 23 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 9 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 105 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | terminated | Phase 1 | 3 | Jorge J. Castillo, MDOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | terminated | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | terminated | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 9 | GlaxoSmithKlineINDUSTRY | 3 | Mar 12, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | terminated | Phase 1 / Phase 2 | 9 | BioNova Pharmaceuticals (Shanghai) LTD.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | terminated | Phase 1 | 4 | Anaveon AGINDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT04912427 | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | terminated | Phase 1 | 1 | Washington University School of MedicineOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 136 | ADC Therapeutics S.A.INDUSTRY | 6 | Feb 6, 2024 | clinicaltrials |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03502577 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma | terminated | Phase 1 | 19 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | terminated | Phase 1 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | terminated | Phase 1 | 6 | Vincerx Pharma, Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | terminated | Phase 1 / Phase 2 | 3 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | terminated | Phase 1 | 98 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03318861 | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 17 | Kite, A Gilead CompanyINDUSTRY | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 1 / Phase 2 | 6 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | terminated | Phase 1 / Phase 2 | 32 | Sherif Farag, MB, BSOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | terminated | Phase 1 / Phase 2 | 55 | SecuraBioINDUSTRY | 6 | Sep 28, 2023 | clinicaltrials |
| NCT04692155 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)(CHOP U2) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04142619 | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) | terminated | Phase 1 | 11 | Cellectis S.A.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04171843 | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 48 | Precision BioSciences, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 42 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05698888 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | terminated | Phase 1 | 2 | Virtuoso BINco, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | terminated | Phase 1 | 4 | Washington University School of MedicineOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | terminated | Phase 1 | 9 | AstraZenecaINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | terminated | Phase 1 | 12 | University of WashingtonOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02588456 | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT01728259 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | terminated | Phase 1 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 2 | May 9, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2024source: clinicaltrials